• Selective mRNA transport and translation regulates BRAF inhibitor sensitivity in BRAF V600 melanoma cells.
Summary
Despite the success of therapies targeting oncogenes in cancer, clinical outcomes are limited by drug adaptation and resistance. BRAF inhibition in melanoma results in multiple cellular adaptations that precede resistant disease, including altered metabolism. Here, we use a genome-wide RNAi screen to identify mRNA transport and translation as regulators of metabolic response and adaptation following BRAF inhibition in melanoma cells. Mechanistically, we demonstrate the RNA binding kinase UHMK1 interacts with mRNAs that encode metabolic proteins and selectively controls their transport and translation. Importantly, genetic inactivation of UHMK1 delays resistance to BRAF and MEK combination therapy in vivo. Our data support a model wherein selective mRNA transport and translation is activated in response to therapeutic stress and contributes to metabolic adaptation underpinning therapeutic response. Inhibition of this process may extend efficacy of targeted therapies in oncogene driven cancers that rely on RAS-MAPK signaling networks.
Introduction
Therapeutic adaptation is a multifaceted process that if overcome offers the potential for significant improvement in clinical outcomes for patients treated with targeted therapies.
Maximising inhibition of oncogenic signaling has been the prevailing paradigm for improving antitumor responses to targeted therapies. This concept is exemplified in melanoma where maximal suppression of BRAF-MEK signaling using combination therapy has extended median survival to over 24 months from a historical base of less than 12 months (Larkin et al., 2014; Robert et al., 2015) . Despite this, development of resistance remains a challenge for patients with advanced melanoma, and significantly, more than 20 mechanisms of resistance have been identified in patients progressing on targeted therapy (Lim et al., 2017) . This highlights the need to improve therapeutic response before mutational resistance emerges. Prior to relapse, acquisition of a drug tolerant state occurs during early adaptive responses to BRAF and MEK targeted therapy in melanoma (Menon et al., 2015; Rambow et al., 2018; Sharma et al., 2010; Su et al., 2017) , and it has been proposed that non-mutational mechanisms underpinning this adaptability may provide new targets to improve therapeutic efficacy.
Altered metabolism is a hallmark of cancer that has been intensely investigated over the last decade. How therapy reprograms metabolism and the role this plays during the adaptive response and development of resistance has received much less attention. In the setting of melanoma, we have previously shown that BRAF V600 inhibitor sensitivity correlates with glycolytic response in pre-clinical (Parmenter et al., 2014) and clinical studies (McArthur et al., 2012) . BRAF inhibition (BRAFi) also renders BRAF V600 melanoma cells addicted to oxidative phosphorylation (OXPHOS) by releasing BRAF mediated inhibition of a MITF-PGC1A-OXPHOS pathway (Haq et al., 2013) . This unleashes adaptive mitochondrial reprogramming, ultimately facilitating drug tolerance likely by compensating for suppressed glycolysis. Consistent with these observations, a "nutrient-starved" cell state emerges during the early drug adaptation phase following combined BRAF and MEK inhibition in vivo, and critically, cells appear to transition through this adaptive state as they acquire resistance . Clinically, PGC1α (a biomarker for elevated OXPHOS) is induced in BRAF V600 melanoma patients treated with BRAFi, either alone (Haq et al., 2013) or in combination with MEK inhibitors (Gopal et al., 2014) , whilst tumors that relapse following MAPK inhibitor treatment display an elevated mitochondrial biogenesis signature (Zhang et al., 2016) . Together, these data suggest that maximal suppression of glycolysis and concurrent inhibition of adaptive mitochondrial metabolism may lead to improved therapeutic outcomes and interfere with drug adaptation following BRAF and MEK targeted therapy. Notably, however, early results emerging from clinical trials of mitochondrial inhibitors such as biguanides have been largely disappointing (Kordes et al., 2015) , and recent preclinical analyses support the concept that mechanisms underlying metabolic plasticity and adaptation may represent a more attractive therapeutic target (Hulea et al., 2018) .
Here, we examined metabolic reprogramming in the therapeutic adaptation phase prior to acquired resistance using a genome-wide RNAi screen. This systematic approach uncovered mRNA transport and translation pathways as critical regulators of metabolic response and adaptation following BRAFi in BRAF V600 melanoma cells. Mechanistically, we demonstrate that metabolic adaptation is associated with selective mRNA transport and translation of metabolic proteins critical to BRAF inhibitor sensitivity and resistance, including glucose transporters and OXPHOS enzymes. This translational reprograming is mediated by the RNA binding kinase UHMK1 that is required for mitochondrial flexibility in response to BRAFi and controls the abundance of metabolic proteins through the export and translation of the mRNA that encode them. Importantly, genetic inactivation of UHMK1 increases sensitivity to BRAF and MEK combination therapy and delays resistance in vivo. Together, our data support a model wherein selective mRNA transport and translation contributes to the metabolic adaptation that underpins therapy induced cancer cell plasticity, and suggests inhibition of this pathway may delay resistance to MAPK pathway targeted therapies.
Results

RNA binding, transport and translation pathways regulate metabolic response to BRAF inhibition.
To identify new regulators of metabolic response to BRAF inhibition (BRAFi), we performed a genome wide RNAi glycolysis screen in BRAF V600 melanoma cells treated with the BRAFi vemurafenib (Vem)( Figure 1A ). Lactate is routinely used to measure glycolysis and can be readily detected in growth medium using a lactate dehydrogenase (LDH) enzyme based reaction. Cell number and viability were determined from nucelar DAPI staining using automated image analysis. For the screen, cells were first transfected with the human siGENOME SMARTPool library and subsequently treated with DMSO or a sub maximal dose of Vem (~IC25)( Figure 1A ). We chose a 48hr treatment which is within the window of metabolic adaptation following BRAFi, whereby maximal suppression of glycolysis (Parmenter et al., 2014) and adaptive mitochondrial reprogramming ( (Haq et al., 2013; Zhang et al., 2016) ; Figure S1A ) is observed. Notably, increased expression of SLC7A8 (LAT2), a biomarker of a drug tolerant "starved" melanoma state following BRAFi+MEKi in vivo , was also observed ( Figure S1B ). Transfection of WM266.4 BRAF V600 cells with siRNA targeting polo-like kinase 1 (PLK1; death control) and pyruvate dehydrogenase kinase 1 (PDK1; glycolysis control) were used to define the dynamic range of the screening assays ( Figure 1B) , and notably, glycolysis was significantly more attenuated in Vem+siPDK1 cells compared to either Vem or siPDK1 alone, providing proof of principle for the major aim of the screen.
In the absence of drug, viability was impaired by depletion of 622 genes (Table S1 ) that formed a robust network ( Figure S2A ) enriched for regulators of cell cycle, translation and the ribosome ( Figure S2B ), processes previously shown to be critical for melanoma survival (Boussemart et al., 2014; Feng et al., 2015; Kardos et al., 2014) . Glycolysis was reduced by depletion of 164 genes (Table S2) , and as expected these genes were enriched with annotations associated with metabolism ( Figure S2C and Table S2 ). To identify genes that regulate viability and glycolytic response to BRAFi, genes were grouped based on fold change data for each parameter in DMSO versus Vem treatment conditions (see supplementary information). This analysis identified 717 genes (Table   S3 ) that were enriched for MAPK and GPCR signaling, and histone methylation, consistent with previous studies investigating BRAFi resistance ( Figure 1C & Figure   S2D ) (Johannessen et al., 2013) . However, the most striking feature of the gene set was RNA binding and transport, which was associated with 4 of the top 20 annotations ranked by P-value ( Figure 1C & Table S3 ), with a total of 12 annotations associated with these pathways enriched in the dataset (Table S3 ). The identification of RNA binding and transport proteins in our screen was particularly intriguing given these proteins are emerging as key determinants of gene expression programs activated in response to microenvironmental stress (El-Naggar and Sorensen, 2018) . This group also included components of the EIF3 and EIF4F translation initiation complexes, and genes that regulate selective mRNA translation, thus also implicating mRNA translation in glycolytic responses to Vem. Notably, EIF4F has previously been reported as a nexus of resistance to MAPK pathway inhibitors in melanoma (Boussemart et al., 2014) thus further supporting performance of the screen. Comparative network analysis revealed 3 major hubs connect the viability and glycolysis networks; 1. GPCR signaling, 2. MAPK signaling, and 3. RNA transport and translation ( Figure 1D ), suggesting these pathways may coordinately regulate metabolic and viability responses to BRAFi. Consistently, 7 of the RNA transport and translation genes also enhanced the effects of Vem on viability ( Figure 1E ). The major findings of the screen were confirmed using a secondary deconvolution screen, whereby four individual siRNA duplexes were assessed to determine reproducibility of gene knockdown phenotypes. Notably, multiple RNA transport and translation genes were validated by 2 or more duplexes (33%; Figure   S2E ). We next assessed changes in expression of the RNA binding, transport and translation gene set using a published transcriptomic analysis of melanoma patients progressing after treatment with BRAF+/-MEK inhibitor treatment (Hugo et al., 2015) . Strikingly, this analysis revealed that 18 out of 23 (78%) RNA transport and translation genes were upregulated in 10-36% of patients progressing on BRAF+/-MEK inhibitor treatment ( Figure 1F & Table S4 ). By way of comparison, PGC1A was upregulated in 43% of patients in this dataset, whilst other previously documented biomarkers of acquired resistance to MAPK pathway inhibition in patients, c-MET and AXL, were upregulated in 33% of patients ( Figure 1F ). Viewed together, these large scale and unbiased analyses support a role for RNA binding, transport and translation pathways in regulation of metabolic response and viability following BRAFi.
Depletion of the RNA transport and translation regulators UHMK1 and YBX1
sensitizes BRAF V600 melanoma cells to BRAFi.
Among these RNA binding proteins we further investigated the roles of U2AF homology motif kinase 1 (UHMK1) and Y-box binding protein 1 (YBX1) in regulation of metabolic response to BRAFi in a panel of BRAF mutant melanoma cell lines (Figure 2 & S3 ). Both these proteins regulate cellular adaptation via selective RNA transport and translation (Cambray et al., 2009; El-Naggar et al., 2015; Evdokimova et al., 2009; Kosnopfel et al., 2018; Pedraza et al., 2014) thus we hypothesized they may also regulate metabolic reprogramming via RNA processing in the context of adaptation following BRAFi. First, UHMK1 and YBX1 knockdown was confirmed using qRT-PCR and western blotting ( Figure S3A ). Because UHMK1 lacks a specific antibody for the endogenous human protein, we also confirmed increased levels of its key target p27, which is degraded following phosphorylation by UHMK1 (Boehm et al., 2002) . siUHMK1+Vem and siYBX1+Vem treated cells showed more attenuated lactate production (Figure 2A was of most interest given it is the only known kinase to contain a classical RNA binding domain (the U2AF homology domain), suggesting it may function as a critical hub linking cell signaling and RNA processing to metabolic reprogramming. The kinase domain of UHMK1 shows limited homology to known kinases, however a K54A mutation in the putative active site extinguishes kinase activity (Maucuer et al., 1997) . In order to establish the contribution of UHMK1 kinase activity in BRAFi response, we first genetically inactivated UHMK1 using CRISPR-Cas9 and confirmed increased sensitivity of A375 cells to BRAFi (Figure 2H & S3G) . Importantly this effect was rescued by expression of UHMK1-V5, but not the kinase dead K54A-V5 mutant ( Figure 2H ). UHMK1 expression and activity was confirmed using qRT-PCR and western blot analysis ( Figure S3G ). Viewed together, this data confirms a role for the kinase function of UHMK1 in therapeutic responses to BRAF inhibition in melanoma cells.
UHMK1
reprograms metabolism in response to BRAFi in BRAF V600 melanoma Cells.
We next investigated whether UHMK1 can also promote adaptive reprogramming of metabolism in response to BRAFi in melanoma cells. Due to cell death after 72hr treatment with Vem+siUHMK1 ( Figure 2G ), we assessed cells after 48hr which immediately precedes overt mitochondrial reprogramming ( Figure S1A ). Analysis of oxygen consumption rates (OCR) using Seahorse extracellular flux analysis ( Figure 3A) revealed only modest effects on basal and maximal OCR ( Figure 3B & C) in Vem+siUHMK1 treated cells. However, significant reductions in spare respiratory capacity ( Figure 3D ) and ATP production ( Figure 3E ) were observed, indicating a reduced ability to respond to changes in energy demand and suggesting that UHMK1
can promote mitochondrial flexibility in response to BRAFi. Impaired mitochondrial metabolism in Vem+siUHMK1 treated cells was not associated with reduced mitochondrial number ( Figure 3F ), moreover only modest effects on PGC1A mRNA expression was observed ( Figure 3G ). We also assessed expression of mitochondrial transcription factor A (TFAM), another key regulator of mitochondrial biogenesis, and again saw no evidence of a role for UHMK1 in its expression. Instead, analysis of OXPHOS protein levels following Vem treatment revealed increased expression of several OXPHOS proteins (NDUFB8, SDHB, UQCRC2, MTCO1), with the exception of ATP5A from complex V ( Figure 3H ), and importantly, this increase in OXPHOS proteins was UHMK1 dependent ( Figure 3H ). Together this data suggests that UHMK1 is required for regulation of oxidative metabolism following BRAFi by modulating OXPHOS protein expression independent of changes in the PGC1A-or TFAM-mitochondrial biogenesis transcription factor networks.
UHMK1 binds to mRNA encoding metabolic proteins and regulates their nuclearcytoplasmic transport in BRAF V600 melanoma cells adapting to BRAFi.
To understand how UHMK1 regulates metabolic response and adaptation following BRAFi, we next employed a systematic approach to look at mRNA expression pathways from transport to translation. The effect of Vem and UHMK1 knockdown on nuclearcytoplasmic mRNA transport was first assessed using RNA fluorescence in situ hybridization (FISH) with an oligo(dT) probe which specifically binds to poly(A) + pools of RNA ( Figure 4A ). In control conditions, the poly(A) + signal was predominantly equal between the nucleus and cytoplasm ( Figure 4A ), however in contrast, depletion of the principal mRNA export factor NXF1 caused accumulation of the poly(A) + signal in the nucleus ( Figure 4A -B). Notably, nuclear accumulation of poly(A) + mRNA was also observed in UHMK1 depleted cells, confirming a role for UHMK1 in mRNA transport in the context of melanoma cells. BRAFi also gave rise to a significant increase in the poly(A) + nuclear to cytoplasm ratio ( Figure 4B ), however no further change was observed in the siUHMK1+Vem and siNXF1+Vem treated cells.
The modest phenotype of UHMK1 compared to NXF1 depletion indicated a more selective role for UHMK1 in mRNA transport. To extend these observations, we next assessed nuclear-cytoplasmic transport of specific mRNA transcripts using qRT-PCR analysis of nuclear and cytoplasmic mRNA pools generated from subcellular fractionation. The fractionation was verified by monitoring levels of mRNA known to be enriched within the nucleus (metastasis associated lung adenocarcinoma transcript 1; MALAT1) and cytoplasm (ribosomal protein S14; RPS14)( Figure S4A ). We focused on mRNA encoding core proteins that function in glycolysis (glucose transporter 1 (GLUT1), hexokinase 2 (HK2)) and OXPHOS (PGC1A, ubiquinol-cytochrome c reductase core protein 2 (UQCRC2; complex III), ATP synthase F1 subunit alpha (ATP5A; complex V)).
Notably, reduced cytoplasmic mRNA (UQCRC2) and increased nuclear mRNA (GLUT1 & HK2; Figure Together, these observations suggest that UHMK1 can selectively regulate nuclearcytoplasmic mRNA transport in the context of therapeutic adaptation in BRAF V600 melanoma cells following BRAFi.
UHMK1 directly regulates localization and translation of specific mRNA transcripts by binding to mRNA (Cambray et al., 2009; Pedraza et al., 2014) . To determine whether UHMK1 directly regulates mRNA encoding metabolic proteins following BRAF inhibition, we performed RNA immunoprecipitation (RNA-IP) assays using UHMK1-V5 expressing melanoma cells following DMSO or Vem treatment ( Figure S4C ). Strikingly, GLUT1, UQCRC2 and HK2 mRNA were not found in association with UHMK1-V5 in treatment naïve cells, however a significant increase in their association was observed following
Vem treatment (Figure 4F & S4D) . Further indicating specificity of the analysis and the pathway, no PGC1A mRNA could be detected in association with UHMK1 in any condition ( Figure 4F ). These data provide evidence that UHMK1 can directly regulate GLUT1, HK2, and UQCRC2 mRNA transport by physically associating with their mRNA, and strikingly, this association is induced by BRAFi.
UHMK1 associates with polysomes and regulates selective translation of mRNA encoding metabolic proteins following BRAFi.
To test the hypothesis that regulation of mRNA transport by UHMK1 selectively promotes translation of metabolic proteins following BRAFi, we next characterized the translational response of UHMK1 target genes following BRAFi. First, we isolated mRNA bound to ribosomes using poly-ribosome (polysome) profiling ( Figure 5A ). Cell lysates were fractionated on a sucrose density gradient to isolate mRNA or proteins in subpolysome (mRNP complexes and 40S, 60S, and 80S monomer peaks) or actively translating polysome (3 or more ribosomes) fractions (Gandin et al., 2014) . Global polysome profiles generated from control treated A375 cells revealed a high basal rate of translation, and strikingly, this was potently suppressed by BRAFi for either 24 or 40 hours ( Figure 5B ). In contrast, analysis of the UHMK1 target gene UQCRC2 revealed redistribution of its mRNA from untranslated sub-polysome fractions following 24hr Vem treatment to actively translating polysome fractions 40hr post treatment ( Figure 5C ), independent of changes in total mRNA levels ( Figure 5D ). Notably, translational inhibition of a housekeeping gene NONO was maintained throughout the treatment ( Figure S5A ), moreover, no change in ATP5A ( Figure 5C ) or PGC1A ( Figure S5A ) mRNA translation efficiency was observed throughout the treatment. Together this data supports selective regulation of UQCRC2 mRNA translation following BRAFi, independent from changes in transcription or mRNA stability. We next extended this analysis to UHMK1 glycolytic targets, reasoning translational reprogramming may also underlie UHMK1's role in mediating reduction in glycolysis following BRAFi. Despite a significant reduction in total mRNA levels ( Figure 5D ), GLUT1 mRNA was present predominantly in polysome fractions in all treatment conditions ( Figure 5C -D) consistent with the phenomena of "translational buffering", whereby the rate of mRNA translation efficiency is maintained despite a decrease in total mRNA levels (McManus et al., 2014) .
This observation suggests that any GLUT1 mRNA remaining in cells following BRAFi is translated at high efficiency. Although HK2 mRNA translation initially decreased following 24hr Vem treatment, a redistribution to heavy polysome fractions was observed after 40hr. Overall, this analysis supports a model whereby a highly selective translation program regulates mRNA encoding metabolic proteins in response to therapeutic stress in BRAF V600 melanoma cells. To directly establish if UHMK1 plays a role in this process, we next analyzed de novo synthesis of proteins by giving a pulse with the methionine analogue L-azidohomoalanine (AHA), which is incorporated into all newly synthesized proteins, followed by biotin labeling, streptavidin pull-down, and western blot analysis ( Figure 5Ei ). Consistent with our polysome profile analysis, we observed a striking decrease in total AHA-labelled protein indicating a global inhibition of protein synthesis following 72hr Vem treatment (Figure 5Eii ). In contrast, analysis of OXPHOS proteins following Vem treatment revealed a significant increase in de novo synthesis of UQCRC2 ( Figure 5F ), and significantly, increased synthesis of this OXPHOS protein was UHMK1 dependent. Again, supporting specificity of this pathway, no significant change in synthesis of ATP5A protein was observed ( Figure 5F ), consistent with polysome profiling of ATP5A mRNA ( Figure 5C ). Strikingly, we also observed that although GLUT1 protein synthesis was decreased following Vem treatment, this reduction was significantly more pronounced following UHMK1 knockdown ( Figure 5F ). This data suggests that UHMK1 depletion may cooperate with
BRAFi to elicit a double-hit on the glycolysis pathway, whereby both GLUT1 mRNA transcription and translation is concurrently switched off. Linking these observations to UHMK1's role in cellular responses to BRAFi, depletion of UQCRC2 and GLUT1 phenocopy UHMK1 knockdown whereby enhanced sensitivity to BRAFi was observed in cell proliferation assays (Figure S5C-E and (Parmenter et al., 2014) ). However in contrast, no effect on Vem sensitivity was observed in the context of Vem+siATP5A treated cells ( Figure S5E ). Together, this data supports a model whereby UHMK1
regulates glycolysis and mitochondrial metabolism following BRAFi via mRNA transport and translation.
The mechanistic target of rapamycin (mTOR) pathway regulates translation and anabolic metabolism in response to nutrient supply (Ben-Sahra and Manning, 2017) and has been linked with a high OXPHOS phenotype in BRAF and MEK inhibitor resistance in melanoma cells (Gopal et al., 2014) . Notably, although mTOR signaling was suppressed following BRAFi ( Figure S6 ), no further changes to this pathway were observed following UHMK1 depletion, suggesting UHMK1 functions in an alternative pathway to modify mRNA translation during the early adaptation phase in cells treated with BRAFi. Differential association of mRNA processing and transport proteins with polysomes, and selective delivery of the transcripts they associate with, is another attractive hypothesis to explain translation of selective transcripts. To further explore the role of UHMK1 in adaptive programs following BRAF therapy, we precipitated proteins associated with polysomes using UHMK1-V5 expressing cells treated with DMSO or Vem ( Figure 5G ). As expected, small ribosomal protein RPS6 (a 40S ribosome component) was distributed in all fractions in control conditions, whilst large ribosomal protein RPL11 (an 80S ribosome component) was absent from early mRNP and 40S fractions. A significant reduction in the polysome to sub-polysome ratio was observed after Vem treatment ( Figure 5H ), consistent with global inhibition of translation ( Figure   5B ). Moreover, tubulin was restricted to sub-polysome fractions in both DMSO and Vem treated samples, further confirming specificity of the analysis ( Figure 5G ). In contrast, UHMK1-V5 protein was predominantly associated with sub polysome fractions in control conditions, however a redistribution of the protein to actively translating polysome fractions was observed following Vem treatment . This data suggests that not only is UHMK1 recruited to polysomes in melanoma cells, but this association increases in response to BRAF therapy. Consistent with these observations, immunofluorescence analysis revealed a dramatic re-localization of UHMK1 from the nucleus to cytoplasm in cells treated with Vem ( Figure S7 ), and this was not associated with any change in UHMK1 protein levels ( Figure S4Cii ). Together this data supports a model whereby UHMK1 binds to mRNA and is translocated from the nucleus to the cytoplasm in response to BRAFi, where a proportion of the protein (~13%) associates with polysomes and participates in selective regulation of mRNA translation.
Genetic inactivation of UHMK1 sensitizes BRAF V600 melanoma cells to BRAF and MEK combination therapy in vitro and in vivo.
We were next interested in testing the hypothesis that UHMK1 depletion would improve response and delay resistance following treatment with the current standard of care for BRAF V600 melanoma patients, a BRAF+MEK inhibitor combination. Altogether, our findings support a model wherein UHMK1 regulates metabolic response and adaptation following BRAFi by controlling the abundance of metabolic proteins through the selective transport and translation of the mRNA that encode them ( Figure   7 ). Importantly, inactivation of this pathway significantly improved survival following combined BRAF and MEK inhibition in vivo, suggesting inactivation of this pathway may represent a new strategy to delay targeted therapy resistance in melanoma patients.
Discussion
Despite the success of therapies targeting oncogenes in cancer, clinical outcomes are limited by drug adaptation and acquired resistance (Hugo et al., 2015) . An emerging phenomenon observed following inhibition of oncogenic signaling in a range of cancers is adaptive mitochondrial reprogramming and enhanced reliance on oxidative metabolism (Baenke et al., 2015; Biancur et al., 2017; Caino et al., 2015; Ghosh et al., 2015; Haq et al., 2013; Hernandez-Davies et al., 2015; Kluza et al., 2012) . In pancreatic cancer models, cells that survive genetic inactivation of KRAS G12D display elevated mitochondrial metabolism, and treatment with an ATP synthase inhibitor delays relapse (Viale et al., 2014) . Treatment of glioblastoma with PI3K inhibitors drives adaptive mitochondrial reprogramming that is associated with tumor cell invasion (Caino et al., 2015) . Mitochondrial metabolism can also influence drug sensitivity, wherein analysis of melanoma patient samples linked mitochondrial gene expression signatures with intrinsic and adaptive resistance to BRAF and MEK inhibitors (Zhang et al., 2016) .
Inhibitors of oxidative metabolism, or the processes controlling adaptive mitochondrial reprogramming, are therefore attractive targets for combination therapy to circumvent acquired resistance before it can develop in a broad range of cancers. Here, we define a new mechanism of non-genomic drug adaptation whereby adaptive mitochondrial metabolism is regulated at the level of mRNA transport and translation and we identify the RNA binding kinase UHMK1 as central to this process. We propose inactivation of this pathway may represent a new strategy to delay targeted therapy resistance in melanoma patients.
mRNA translation has been implicated in responses to MAPK pathway inhibition and development of resistance in melanoma (Boussemart et al., 2014; Rapino et al., 2018) .
Here, we demonstrate that despite global suppression of translation during the early drug response phase, transcript selective translation reprograms mitochondrial metabolism through upregulation of OXPHOS proteins, and significantly, we show this is UHMK1 dependent. Importantly, upregulation of these mitochondrial proteins also occurs in melanoma patients progressing on BRAF and MEK targeted therapy (Zhang et al., 2016) , linking these observations to resistance mechanisms in patients.
Translational "buffering" (McManus et al., 2014) of glycolysis genes, whereby the rate of mRNA translation efficiency is maintained despite a decrease in total mRNA levels, also emerged from our analysis, and de novo protein synthesis assays revealed GLUT1 translation was maximally suppressed following UHMK1 depletion in combination with
BRAFi. Viewed in the context of previous studies describing transcriptional repression of GLUT1 following BRAFi , this data supports a model whereby UHMK1 depletion cooperates with BRAFi to elicit a double-hit on the glycolysis pathway, whereby both GLUT1 mRNA transcription and translation is concurrently switched off. Consistent with these observations, Rapino et al (Rapino et al., 2018) regulates their selective transport and translation. We suggest this mechanism allows cells to rapidly respond to cellular stimuli and stress such as nutrient deprivation.
Interestingly, differential association of mRNA binding proteins with polysomes is one mechanism cells employ to rapidly regulate transcript selective translation (Aviner et al., 2017) , and association of UHMK1 protein with polysome fractions following BRAFi is consistent with this concept. Moreover, a recent proteomic analysis of polysomes revealed 45% of all proteins identified were annotated as RNA binding, and a significant proportion of these were regulators of RNA transport and processing (Aviner et al., 2017) . Notably, 78% of the RNA transport and translation gene set identified by the screen were upregulated in 10 -36% of patients progressing on BRAF +/-MEK inhibitor treatment. Importantly, this is comparable to documented biomarkers of acquired resistance to MAPK pathway inhibition in melanoma patients, including PGC1A (43%), AXL (33%) and c-MET (33%) (Hugo et al., 2015) , indicating relevance of these findings to human disease. Further analyses are now required to identify gene expression signatures associated with dysregulation of UHMK1 and other selective RNA binding and transport pathways in order to comprehensively assess their role in early adaptation and acquired resistance to MAPK targeted therapies in cancer patients.
Our data suggests that UHMK1 inactivation does not influence selective RNA transport and translation through mTOR signaling, however UHMK1 activity is regulated by both AKT and ERK signaling in the context of growth factor stimulation (Lee and Kay, 2011) . Viewed collectively, our work supports a model wherein selective mRNA transport and translation is activated in response to therapeutic stress and contributes to metabolic reprogramming underpinning the adaptive therapeutic response. Our data demonstrate that the RNA binding kinase UHMK1 binds to mRNA encoding metabolic proteins critical to BRAFi response, and is required for their transport and translation following BRAFi.
Inactivation of UHMK1 interferes with adaptive mitochondrial reprogramming following
BRAFi, and critically, delays resistance and improves survival following combined BRAF and MEK inhibition in vivo. We propose that selective RNA transport and translation serves as a non-genomic mechanism of cancer cell adaptation and may provide a new target to interfer with drug adaptation and improve the efficacy of targeted therapies. We speculate this mechanism may also be relevant in broader oncogene driven cancer settings where responses to targeted therapies are blunted by phenotypic adaptation involving reprogrammed mitochondrial networks.
STAR Methods
Detailed methods are provided in the online version of this paper and include the following:
• Key resources table Lactate absorbance values were normalised to cell number to determine lactate production per cell (bottom panel). Data is normalised to siOTP non-targeting (siOTP) transfected DMSO controls. Statistical significance was determined using a one-way ANOVA *** p > 0.001 (error bars = SEM, N=3). C. Functional annotation enrichment analysis was performed on 717 genes that enhanced the effects of Vem on lactate production (DMSO lactate per cell ratio < 0.5-fold change and Vem lactate per cell ratio > 0.5-fold change; see Table S1 ) using DAVID. Data is displayed as Log2 fold change versus -Log10 p-value. D. Network analysis was performed on 622 viability screen hits and 717 hits that enhanced the effects of Vem on lactate production using String (see Figure S1 ). Comparative network analysis was performed using Cytoscape, and hubs connecting the two networks are highlighted. E. Heat map displaying viability and lactate screening data for the indicated genes. F. Heatmap displaying percentage of melanoma patients with up-regulation of the indicated mRNA transport and translation genes on progression following treatment with MAPK pathway inhibitors (data sourced from (Hugo et al., 2015) ; see Table S4 ). See also Figure S1 -2. 
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